Alnylam Pharmaceuticals
(ALNY)Financial Overview
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Inc., with CEO Yvonne Greenstreet, is a biopharmaceutical company pioneering RNA interference (RNAi) therapies. Its approved products target rare genetic diseases such as hATTR amyloidosis and acute hepatic porphyria. Greenstreet is leading expansion into CNS and cardiometabolic diseases. Alnylam’s platform is advancing gene silencing for previously untreatable conditions. It is a trailblazer in RNA therapeutics.
Analyst Forecast
Alnylam has established RNA-interference as a commercial drug platform, with growing rare-disease products and a deep pipeline. Clinical outcomes, reimbursement and launch execution drive value. The current valuation assigns substantial credit to future indications, while trial setbacks can be severe. Demand is defensive. Cash discipline and successful expansion beyond the initial franchises are essential.
Analysis by Luigi Wewege
President at Caye International Bank
Luigi Wewege is President of the award-winning Caye International Bank. He is the author of The Digital Banking Revolution, now in its third edition, and of the article “Disruptions and Digital Banking Trends,” published in The Journal of Applied Finance & Banking. Luigi has also co-authored economic research examining the accuracy of credit bureau data, which was presented before the United States Congress. At Caye Bank, his research and strategic insights help guide billions in client portfolio decisions across international markets. Known for his disciplined diversification philosophy, he served as the conceptual architect behind this Portfolio Fit Calculator. He holds an Italian MBA specializing in International Business, and earned his BSBA with a triple major in Finance, International Business, and Management, graduating with Latin Honors from the University of Missouri–St. Louis.
18 years of experience
Should You Buy Alnylam Pharmaceuticals Stock?
This interactive tool helps you determine whether this stock fits into your investment strategy based on your portfolio size, risk tolerance, and allocation preferences.
What this calculator analyzes:
- Risk compatibility between your profile and this stock
- Appropriate allocation size for your portfolio
- Diversification recommendations
- P/E ratio context and valuation analysis
⚠️ This tool is for informational purposes only. It does not constitute financial advice. Investing involves risk, including loss of capital. Always consult a licensed financial advisor before making investment decisions.